Real-world evaluation of oral vinorelbine in the treatment of metastatic breast cancer: An ESME-MBC study

Pierre Heudel, Suzette Delaloge, Damien Parent, Nicolas Madranges, Christelle Levy, Florence Dalenc, Etienne Brain, Lionel Uwer, Veronique D'Hondt, Paule Augereau, Audrey Mailliez, Christophe Perrin, Jean Sebastien Frenel, Marie Paule Sablin, Marie Ange Mouret-Reynier, Thomas Vermeulin, Jean Christophe Eymard, Thierry Petit, Jean Marc Ferrero, Silvia IlieAnthony Goncalves, Gaëlle Chenuc, Mathieu Robain, Gaëtane Simon, David Perol

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    6 Citations (Scopus)

    Résumé

    Background/Aim: Vinorelbine is indicated for use in the treatment of MBC as a single agent or in combination but there is little real world data on this molecule and even less on its oral form. We exploited the Unicancer Epidemiology Strategy Medical-Economics (ESME) metastatic breast cancer (MBC) database to investigate current patterns of use of oral vinorelbine (OV), as well as outcomes of patients receiving this drug. Patients and Methods: Data were collected retrospectively from women and men treated for MBC between 2008 and 2014 at one of 18 French Comprehensive Cancer Centres. The efficacy of OV was evaluated in terms of progression-free (PFS) and overall survival (OS) and treatment duration. The population and patterns of OV usage were also described. Results: A total of 1806 patients (11% of the ESME MBC database) were included in this analysis. OV was prescribed as monotherapy (46%) or in combination (29%), especially with capecitabine. mainly in later treatment lines. Median PFS was 3.3 months: 2.9 months for single agent, 3.6 months for combination therapy. Median OS was 40.9 months. Conclusion: Real-world data offer complementary results to the data from traditional clinical trials, but they concern a much larger population. In this ESME MBC cohort, OV was only prescribed to a small subset of MBC patients. OV was mainly given as single agent to patients with heavily pretreated MBC; less commonly, it was co-administered with capecitabine or anti-HER2, in earlier lines of therapy. PFS was modest but in line with previous reports.

    langue originaleAnglais
    Pages (de - à)3905-3913
    Nombre de pages9
    journalAnticancer Research
    Volume40
    Numéro de publication7
    Les DOIs
    étatPublié - 1 juil. 2020

    Contient cette citation